Premium
Prostate cancer detection using quantitative T 2 and T 2 ‐weighted imaging: The effects of 5‐alpha‐reductase inhibitors in men on active surveillance
Author(s) -
Giganti Francesco,
Gambarota Giulio,
Moore Caroline M.,
Robertson Nicola L.,
McCartan Neil,
Jameson Charles,
Bott Simon R.J.,
Winkler Mathias,
Whitcher Brandon,
CastroSantamaria Ramiro,
Emberton Mark,
Allen Clare,
Kirkham Alex
Publication year - 2018
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.25891
Subject(s) - dutasteride , medicine , prostate cancer , nuclear medicine , prostate , placebo , mann–whitney u test , population , cancer , urology , pathology , alternative medicine , environmental health
Background T 2 ‐weighted imaging (T 2 ‐WI) information has been used in a qualitative manner in the assessment of prostate cancer. Quantitative derivatives (T 2 relaxation time) can be generated from T 2 ‐WI. These outputs may be useful in helping to discriminate clinically significant prostate cancer from background signal. Purpose/Hypothesis To investigate changes in quantitative T 2 parameters in lesions and noncancerous tissue of men on active surveillance for prostate cancer taking dutasteride 0.5 mg or placebo daily for 6 months. Study Type Retrospective. Population/Subjects Forty men randomized to 6 months of daily dutasteride ( n = 20) or placebo ( n = 20). Field Strength/Sequence Multiparametric 3T MRI at baseline and 6 months. This included a multiecho MR sequence for quantification of the T 2 relaxation times, in three regions of interest (index lesion, noncancerous peripheral [PZ] and transitional [TZ] zones). A synthetic signal contrast (T 2 Q contrast) between lesion and noncancerous tissue was assessed using quantitative T 2 values. Signal contrast was calculated using the T 2 ‐weighted sequence (T 2 W contrast). Assessment Two radiologists reviewed the scans in consensus according to Prostate Imaging Reporting and Data System (PI‐RADS v. 2) guidelines. Statistical Tests Wilcoxon and Mann–Whitney U ‐tests, Spearman's correlation. Results When compared to noncancerous tissue, shorter T 2 values were observed within lesions at baseline (83.5 and 80.5 msec) and 6 months (81.5 and 81.9 msec) in the placebo and dutasteride arm, respectively. No significant differences for T 2 W contrast at baseline and after 6 months were observed, both in the placebo (0.40 [0.29–0.49] vs. 0.43 [0.25–0.49]; P = 0.881) and dutasteride arm (0.35 [0.24–0.47] vs. 0.37 [0.22–0.44]; P = 0.668). There was a significant, positive correlation between the T 2 Q contrast and the T 2 W contrast values ( r = 0.786; P < 0.001). Data Conclusion The exposure to antiandrogen therapy did not significantly influence the T 2 contrast or the T 2 relaxation values in men on active surveillance for prostate cancer. Level of Evidence: 4 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2018;47:1646–1653.